
|Videos|October 12, 2017
Fosfomycin: A Novel Epoxide Antimicrobial
Author(s)Contagion® Editorial Staff
Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.
Advertisement
Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a novel antimicrobial. She also shares what the drug’s unique mechanism of action is.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Growing International Evidence Suggests Emerging Metallo-β-Lactamase Therapy Could Benefit US Clinicians
2
CDC's Latest Hepatitis B Vaccine Guidance Serves as Example for Future Federal Vaccine Policy
3
Antibiotic De-Escalation Demonstrates Advantages for Community-Onset Sepsis
4
Addressing the Three Pillars of PPE in Caring for Patients with High-Consequence Infectious Disease
5





























































































































































































































































































































